ETS2 is a transcription factor encoded by a gene on human chromosome 21 and alterations in its expression have been implicated in the pathophysiological features of Down syndrome (DS). This study demonstrates that overexpression of ETS2 results in apoptosis. This is shown in a number of circumstances, including ETS2-overexpressing transgenic mice and cell lines and in cells from subjects with DS. Indeed we report for the first time that the ETS2 overexpression transgenic mouse develops a smaller thymus and lymphocyte abnormalities similar to that observed in DS. In all circumstances of ETS2 overexpression, the increased apoptosis correlated with increased p53 and alterations in downstream factors in the p53 pathway. In the human HeLa cancer cell line, transfection with functional p53 enables ETS2 overexpression to induce apoptosis. Furthermore, crossing the ETS2 transgenic mice with p53 À/À mice genetically rescued the thymic apoptosis phenotype. Therefore, we conclude that overexpression of human chromosome 21-encoded ETS2 induces apoptosis that is dependent on p53. These results have important consequences for understanding DS and oncogenesis and may provide new insights into therapeutic interventions.
INTRODUCTION
Down syndrome (DS), which is caused by an extra copy of chromosome 21, affects all major organ systems including the bone, immune, central nervous and cardiovascular systems (1) and includes a reduced incidence of solid tumours and an increased incidence of childhood leukemias (2, 3) . Since chromosome 21 was sequenced (4), the major challenge in DS research is to identify the normal function of the 225 predicted genes and, importantly, to determine how overexpression of these genes contributes to the pathophysiological features of DS. Since the pathological features of Down syndrome also occur in the general population, albeit less severely and later in life, elucidation of the function of chromosome 21 genes has important implications for major human diseases.
The gene that encodes ETS2 is located on human chromosome 21q22.3 (5) , and has been reported to be overexpressed in brain and fibroblasts from subjects with DS (6, 7) . ETS2 is a member of the Ets family of transcription factors, which has been proposed to have important functions in cancer, bone development and immune responses (8, 9, 12) . Its overexpression could therefore contribute to features of Down syndrome related to these functions. It is currently known that Ets proteins recognize GGAA/T core sequences in promoters of target genes which, using in vitro model systems, have been found to include stromelysin-1, urokinase plasminogen activator, ICAM-1, PLA 2 P, Presenilin-1, Cyclin D1, Jun B, Gadd45, p21/ cip1, p19ARF and p53 (10) . While the identification of such target genes implies that ETS2 may be important in normal processes such as cell cycle regulation or tissue remodeling or in diseases such as cancer, little is known about proven in vivo functions of ETS2.
Therefore, in order to determine the in vivo function(s) of ETS2 and the contribution of its overexpression to the pathophysiological features of Down syndrome, we generated ETS2 transgenic mice that were previously reported to exhibit craniofacial and bone abnormalities resembling those seen in DS (11) . In the present study we further demonstrate that moderate overexpression of ETS2 in the thymus and spleen (not shown) of the transgenic mice and in murine and human cell lines leads to increased apoptosis that requires p53. Importantly, elevated levels of ETS2, an increase in apoptosis and a similar deregulation of the p53 pathway is observed in DS tissues and cell lines, strongly suggesting that increased ETS2 contributes to DS pathogenesis by increasing p53 dependent apoptosis.
RESULTS

Transgenic mice overexpressing ETS2 display hypocellularity of the thymus and increased apoptosis
The thymi of three independent lines of ETS2-overexpressing mice (11), CH1, MR 10.3 and MR 10.5, were examined for several criteria of thymus function. Firstly, the thymi of ETS2-overexpressing mice were significantly decreased in size (Fig. 1A) . At 4 weeks of age the total cell number of the thymi was reduced by 70 AE 23% (n ¼ 14) in line CH1, 42 AE 18% (n ¼ 4) in line MR 10.3 and 27 AE 13% (n ¼ 4) in line MR 10.5, respectively. Flow cytometric analyses of surface antigenstained thymocytes indicated that there were significant reductions in all thymocyte subsets in all three lines, particularly in the proportion of CD 4þ CD 8þ thymocytes (Table 1, CH1 line  shown) . Histologically, the thymi of ETS2 transgenic mice display an ill-defined cortico-medullary boundary, a thin cortex and multiple cysts (Fig. 1B) . The increased frequency of pyknotic nuclei, suggestive of apoptosis, prompted us to examine the extent of apoptosis in more detail.
In situ detection and quantitation of apoptosis in cryosections of the thymus (Fig. 1C ) of CH1 ETS2 transgenic mice revealed an increase in TUNEL positive apoptotic cells compared with non-transgenic littermate controls [121 AE 9.3 cf. 70 AE 7.4 (n ¼ 3), P < 0.05]. Not only was there an increase in apoptosis, but also the apoptotic cells were abnormally distributed in the medulla as well as the cortex of ETS2 transgenic mice. In contrast, in age-matched thymi of 4-week-old control mice, apoptotic cells were detected only in the cortex, indicative of ongoing negative selection. This pattern of apoptosis was mirrored by the distribution of Ets-2 as determined by immunohistochemistry (Fig. 1D) . Similarly, a quantitative increase in apoptosis of isolated thymocytes was observed in all lines. For example, there was a 2-fold increase in apoptosis in the CH1 transgenic line detected by flow cytometry of PI stained cells (29 AE 3% in control cf. to 62 AE 8% in CH1 ETS-2 transgenic mice, Fig. 1E ). This correlated with the 3-fold increase in ETS2 expression in these transgenic thymocytes detected by western blots (Fig. 3) . Increased apoptosis in the transgenic mice also was detected by DNA laddering (data not shown).
Thus, we have demonstrated that, in the thymus of the ETS2 transgenic mouse, the increase in ETS2 correlates with increased levels of apoptosis that could play an important role in the pathological processes described.
Constitutive and inducible overexpression of ETS2 transgenes sensitizes cell lines to apoptosis
In order to investigate whether ETS2 overexpression predisposes other cell types to apoptosis and to demonstrate a direct correlation between induced expression of the ETS2 gene and apoptosis, we next examined fibroblast cell lines expressing constitutive and inducible ETS2 transgenes. First we established that primary embryonic fibroblast cultures from CH1 ETS2 transgenic mice display increased ETS2 expression as shown by western blot analysis ( Fig. 2A) . Next we showed that primary embryonic fibroblast cultures from CH1 ETS2 transgenic mice display increased spontaneous apoptosis in culture, plus markedly increased susceptibility to apoptosis induced by hydrogen peroxide, staurosporin and etoposide ( Fig. 2A) . This result indicates that the apoptosis was a direct, or cell autonomous, effect of ETS2 overexpression. In addition, 3T3 fibroblasts that constitutively overexpress either human ETS2 or murine Ets2 both displayed an increased level of spontaneous and induced apoptosis (Fig. 2B) . In order to demonstrate the acute temporal and concentration dependent nature of ETS2-induced apoptosis in a more tightly regulated system, we next tested 3T3 fibroblasts expressing ecdysoneinducible human ETS2. Addition of up to 8 mg/ml of the ecdysone analogue muristerone to these ETS2 Ec-3T3 fibroblasts leads to a dose-dependent induction of ETS2 of up to 5-fold and a dose-related increase in sensitivity to hydrogen peroxide-induced apoptosis (Fig. 2C) . The data clearly demonstrate that ETS2 overexpression leads to apoptosis in vitro and in vivo; the next compelling question was: which pathway mediates the Ets2-dependent apoptosis?
Ets-2 overexpression correlates with increased activity of the p53 pathway Since overexpression of ETS2 had previously been reported to induce the mRNA levels of the pro-apoptotic molecule, p53 (13), we next tested whether p53 might be involved in the ETS2 mediated apoptosis discovered in the ETS2 transgenic thymus and other experimental situations of ETS2 overexpression described above. In each case, increased ETS2 levels were accompanied by increased p53, namely: (a) thymus from ETS2 transgenic mice (Fig. 3 , left panel, CH1 line); (b) 3T3 fibroblasts stably-transfected with murine Ets2 (Fig. 3 middle  panel) ; and (c) 3T3 fibroblasts transfected with ecdysoneinducible Ets2 (Fig. 3 , right panel, time dependent). Further evidence of activation of the p53 apoptotic pathway was the observation of increased levels of the p53-regulated proapoptotic protein Bax (14, 15) and decreased levels of the p53-regulated anti-apoptotic, Bcl2 (16, 17) (Fig. 3 ). Together these data show that the ETS2-apoptosis pathway and the p53 pathway are linked. Down syndrome tissues and cell lines overexpress ETS2, are predisposed to apoptosis and show deregulation of the p53 pathway
We next determined whether the ETS2-p53-apoptosis pathway correlation demonstrated in our transgenic mouse and cell culture models also existed in cells of subjects with DS. Fibroblast cell lines from subjects with Down syndrome displayed increased spontaneous (2-fold), etoposide-(2.5 fold), hydrogen peroxide-(2-fold) and staurosporin-(3 to 4-fold) induced apoptosis compared with age and passage matched control fibroblast cultures (Fig. 4A ). Western blot analysis of these fibroblast lines from individuals with DS indicated that ETS2 levels are increased, p53 levels are increased and BCL2 levels are reduced (Fig. 4B ). In addition to fibroblasts, other Down syndrome tissues shown to have elevated apoptosis, namely thymus (data not shown) and neurons (18) were also demonstrated to exhibit elevated levels of ETS2, p53 and reduced BCL2 (Fig. 4B ). These data from a human genetic disorder mirror the ETS2 overexpressing transgenic models described above (Figs 1-3 ). Together the results imply that in DS a correlation exists between elevated ETS2, activation of the p53 pathway and increased apoptosis, which could underlie some of the pathological features of this syndrome.
Genetic demonstration that p53 is necessary for Ets2 induced apoptosis of the thymus
In order to demonstrate that the p53 pathway is necessary for ETS2 mediated apoptosis in vivo, we employed the standard genetic procedure of generating compound crosses of genetically modified mouse lines to prove a genetic linkage. Because the p53 À/À mice were on a CBA Â C57 BL/6 background, we first backcrossed the CH1 ETS2 transgenic mice six times to CBA Â C57 BL/6 mice then crossed with p53 À/À mice (19) . The overall thymus size and the total number of viable thymocytes from ETS2 transgenic p53 À/À mice (1.35 AE 0.19 Â 10 8 cells/thymus, n ¼ 4) were increased relative to ETS2 transgenic mice (0.54 AE 0.045 Â 10 8 cells/thymus n ¼ 3, P < 0.05). Indeed the former values were essentially the same as controls (1.47 AE 0.21 Â 10 8 , n ¼ 8), suggesting that this part of the phenotype of ETS2 transgenic mice had been genetically 'rescued' (Fig. 5A ). Furthermore, thymocytes isolated from ETS2 transgenic p53 À/À mice display a significantly reduced rate of spontaneous apoptosis in culture (13 AE 2% apoptosis in ETS2 transgenic p53 À/À mice compared with 33 AE 8% apoptosis in ETS2 transgenic mice, P < 0.05, n ¼ 3; Fig. 5B ). The size, cell number and the rate of spontaneous apoptosis in vitro of the thymus from p53 À/À mice are not significantly different from control mice (results not shown) (20) . These data demonstrate that p53 is necessary (at least in part) for the increase in spontaneous thymic apoptosis and consequent reduced thymus size in ETS2 transgenic mice.
Functional p53 is necessary for Ets2-mediated apoptosis of HeLa cervical carcinoma cells
In order to extend the validation of the dependence of ETS2-induced apoptosis on a functional p53 to a human cell system and to extend previous data on the possible role of ETS2 in cancer, we utilized the HeLa cervical carcinoma cell line, which has transcriptionally inactive p53 that cannot activate its downstream target genes (21) . Upregulation of Ets2 expression in HeLa cells transfected with ecdysone-inducible Ets2 did not lead to an increase in spontaneous apoptosis or an increased sensitivity to hydrogen peroxide induced apoptosis (Fig. 6) . This is consistent with the above results that, in the absence of functional p53, Ets2 overexpression does not induce apoptosis. Subsequent transfection of these HeLa cells with a wild type p53 led to only a modest increase in spontaneous and hydrogen peroxide induced apoptosis, in the absence of Ets2 overexpression; in agreement with previously published data (Fig. 6 ) (22) . However, when Ets2 was simultaneously induced in these p53 transfected HeLa cell lines, a dramatic increase in hydrogen peroxide-induced apoptosis occurred from a basal level of 10 to 65% (Fig. 6) . We therefore conclude that a functional p53 is necessary for Ets2-mediated apoptosis in a human cancer cell line as well as the in vivo model systems like the ETS2 transgenic mouse. and display an increase in spontaneous, hydrogen peroxide, etoposide and staurosporin induced apoptosis relative to controls (blank). Western blots show elevated levels of ETS2 in untreated cells. (B) 3T3 fibroblasts stably overexpressing either human ETS2 (gray) or murine Ets2 (black) display an increase in spontaneous, hydrogen peroxide-, etoposide-and staurosporin-induced apoptosis relative to controls (blank). Western blots show elevated levels of human ETS2 and murine Ets2, respectively. (C) Ec-Ets2-3T3 fibroblasts display a dose-dependent, increased sensitivity to hydrogen peroxide (200 mM, 24h) induced apoptosis after dose dependent induction of Ets2 by 0, 4 and 8 mg/ml of the ecdysone analogue muristerone for 20 h as demonstrated by western blots. The data are presented as the meanAE SD of at least three separate experiments (*P < 0.05, **P < 0.01, ***P < 0.001). For the western blot analyses beta-tubulin was used as a loading control. 
DISCUSSION
In this paper we have examined the effects of overexpression of ETS2 because of its potential role in Down syndrome and related diseases in the general population, such as cancer. ETS2 overexpressing transgenic mouse lines demonstrate abnormalities in the immune system including hypoplasia of the thymus (Fig. 1, Table 1 ), spleen (data not shown) and alterations in peripheral blood (not shown) that are similar to those observed in people with Down syndrome (23, 24) . We demonstrate that the process underlying these changes is an increase in apoptosis. Indeed increased expression of ETS2 predisposes to apoptosis in several defined model systems, including ETS2 transgenic cell lines and transgenic mice, as well as in fibroblasts, neurons and thymi of subjects with Down syndrome. Furthermore, we demonstrated that cells from individuals with Down syndrome are predisposed to apoptosis, consistent with previous reports that primary neuronal cultures (18) and granulocytes (25) from DS individuals show increased apoptotic cell death and that thymocytes from Ts65Dn mice, a mouse model for DS, display increased apoptosis (26) . Therefore, ETS2-induced apoptosis could underlie some of the pathophysiological features of Down syndrome by a similar mechanism to that observed in the mouse and cell models systems studied herein.
In order to investigate the mechanism of ETS2-induced apoptosis we then investigated whether ETS2 might induce apoptosis by activation of the p53 pathway since it had previously been shown to transactivate p53 in 3T3 cells (13) . In all experiments of ETS2 overexpression that we investigated, there was an accompanying increase in levels of p53 [including thymus, spleen, fibroblasts and neurons of ETS2 transgenic mice, ETS2 transfected cell lines 3T3 and L-cells (not shown) plus DS fibroblasts, thymus and neurons]. Further evidence of the involvement of p53 was that alterations in the levels of p53-regulated apoptotic proteins Bcl-2 and Bax also correlated with Ets2 overexpression. These findings of a correlation between Ets2 overexpression and activation of the p53 pathway while strongly implying a direct involvement, required proof that this was the mechanism of Ets2-induced apoptosis.
Because of the limitations of doing conclusive experiments in humans, we chose two model systems in which to demonstrate that p53 was necessary for ETS2-induced apoptosis. Firstly, the ETS2 transgenic mice were crossed with p53 null mice. The apoptotic thymus phenotype evident in the ETS2 transgenic mice was 'rescued' in the ETS2 transgenic p53 À/À mice. Thus, in the absence of p53, ETS2 did not induce apoptosis. The second model was to use the human HeLa cancer cell line in which p53 is not functional. While overexpression of Ets2 did not induce apoptosis in these cells, transfection with wild-type p53 enabled Ets2 overexpression to induce apoptosis. This again demonstrated that Ets2 required functional p53 for induction of apoptosis and broadened the relevance of ETS2-induced apoptosis to the regulation of cancer cells. Interestingly, an increase in p53 and BAX and a reduction in BCL2, which occur in ETS2 overexpressing cells, have been reported in DS brains at sites of apoptotic cell death (27) (28) (29) . This suggests that the mechanism of ETS2-induced apoptosis elucidated in the transgenic mice and human cell line also applies in DS. The implication of these data is that future therapies that target the p53 pathway could have some benefit in ameliorating some of the pathophysiological features of Down syndrome.
The molecular mechanism responsible for the dependence on p53 for ETS2-induced apoptosis has yet to be elucidated. One possibility is that ETS2 transcriptionally upregulates p53. This would be consistent with a previous report in which we demonstrated that overexpression of Ets2 in 3T3 fibroblasts results in increased p53 mRNA, most likely by interaction with several palindromic Ets-binding sites in the p53 promoter (13) . A second (not mutually exclusive) possibility is that ETS2 requires p53 protein-protein interaction. This could occur either directly or indirectly since both ETS2 and p53 can bind to p300 (30) , an interaction that regulates the stability and apoptosis-inducing properties of p53 (31) . These aspects are the subject of ongoing studies.
In addition to the DS features mentioned above, our data may have some relevance to the pathogenesis of cancer. Since individuals with DS also have a reduced incidence of solid tumors (2,3), it was postulated that chromosome 21 might encode one or more tumor suppressor genes (32) . Since our data in this paper show that ETS2 requires p53 for the induction of apoptosis and that DS tissues and cell lines overexpress p53 and ETS2, it is tempting to speculate that the overexpression of ETS2 activates the p53 tumor suppression pathway in DS and thus may contribute to the reduced incidence of solid tumors in DS.
Because of the well-known tumor suppressor activity of p53, our data placing ETS2 upstream of p53 also raise the question of the role of ETS2 in oncogenesis in general. Previous data have been paradoxical. On the one hand ETS2 was shown to be oncogenic in prostate (33, 34) and thyroid (35) cancer cells and 3T3 fibroblasts (12) , cervical (36) and leukemia cancer cell lines (37) (38) (39) . On the other hand, overexpression of ETS2 has been shown to be able to reverse ras-transformation of 3T3 fibroblasts (40, 41) , induce apoptosis in a prostate cancer cell line (42) and regulate tumor suppressor genes such as PLA2P, p19ARF and p53 (10) . Our data helps to resolve the apparent discrepancies over the role of ETS2 in carcinogenesis. While we clearly demonstrate in vivo and in vitro that in many cell types ETS2 is pro-apoptotic, this activity is dependent on the integrity of 'downstream' factors in the pathway such as p53. So, for example, in HeLa cells that have a non-functional p53, upregulation of Ets2 is not pro-apoptotic while, after transfection with wild-type p53, upregulation of Ets2 sensitizes HeLa cells to apoptosis. Indeed ETS2-overexpressing tumour cells could be selected for defects in p53-dependent apoptotic (or other downstream) pathways and thus be more likely to develop a transformed phenotype. In agreement with this notion, activation of the p53 tumor suppression pathway by activated ras was previously suggested to be a failsafe mechanism that allowed the cell to prevent cell transformation (43) (44) (45) (46) .
In summary we conclude that ETS2 overexpression results in an upregulation of p53 protein levels, a downregulation of BCL2, and in increase in BAX levels and consequent increased sensitivity to apoptosis. We propose that the overexpression of ETS2 is an important contributor to the increased susceptibility of DS cells to apoptotic stimuli that might, at least in part, be responsible for the thymic and splenic hypoplasia and conceivably other pathophysiological features shared between ETS2 transgenic mice and individuals with DS. These results might have even broader implications for the role of ETS2 and p53 in pathological processes such as oncogenesis.
MATERIALS AND METHODS
Mouse lines
Three independent ETS2 transgenic mouse lines (CH1, MR 10.3 and MR 10.5) were generated as described previously (11) on a CBA Â C57BL/6 background. In these mice the human ETS2 cDNA is driven by the sheep metallothioneine promoter. The p53 null mice (19) were obtained on a C57BL/6 background. Prior to crossing these mouse strains with the CH1 ETS2 transgenic mice the mice were backcrossed six times to CBA Â C57 BL/6 mice.
Cell lines and culture conditions
3T3 fibroblasts and human control and Down syndrome cell lines were maintained in DMEM containing 10% FCS, 5 mg/ml penicilline and 5 mg/ml streptomycin. L-cells were cultured in RPMI containing 10% FCS 5 mg/ml penicilline and 5 mg/ml streptomycin. Isolated thymocyte suspensions were obtained from freshly removed organs which were subsequently teased through a steel mesh, washed in RPMI, counted and incubated at 5 Â 10 6 cells/ml for 24, 48 and 72 h in RPMI medium with 5 mg/ml b-mercaptoethanol.
For the determination of the sensitivity of cell lines to undergo apoptosis 30-40% confluent cell cultures were either incubated without additions, with 200 mM hydrogen peroxide, 5 mg/ml etoposide or 10 nM staurosporin for 24 h. The amount of apoptosis was subsequently determined by flow cytometry as described below. For determination of apoptosis in Ec-Ets2-3T3 and Ec-Ets2-L-cells, 30-40% confluent cell cultures were incubated in the presence of the indicated amount of muristerone for 20 h prior to addition of 200 mM H 2 O 2 for a subsequent 24 h.
Generation of Ets2-inducible cell lines
Ec-3T3 cells containing the ecdysone receptor fused to a retinoic acid response element were purchased from Invitrogen (San Diego, CA, USA). HeLa cells and L-cells were stably transfected with the ecdysone RXR receptor (Invitrogen, San Diego, CA, USA) to generate Ec-Hela cells. A 1700 bp BamH1 full-length cDNA fragment of murine Ets2 was cloned into the multicloning site of the pIND vector, linearized and stably transfected into both the Ec-3T3 cells, Ec-HeLa cells. After 4 weeks of selection on 400 mg/ml G418 and 500 mg/ml Zeocin, surviving clones were picked, expanded and tested for Ets2 induction by muristerone. Western blotting with an Ets2-specific antibody (Santa-Cruz, sc-351 X) was used to show a dose dependent induction of Ets2 in both Ec-Ets2-3T3 cells, Ec-Ets2-HeLa cells after a 20 h incubation with 0, 4 or 8 mg/ml of the ecdysone analog muristerone. Three Ec-Ets2-HeLa cell lines that displayed muristerone-inducible Ets2 were subsequently transfected with a CMV-p53 expression that bears a hygromycin resistance marker construct (kindly provided by B. Vogelstein). After 3 weeks of selection in 400 mg/ml hygromycin, surviving Ec-Ets2-p53-Hela cells clones were picked, expanded and tested for p53 expression.
Flow cytometry
Multicolor-flow cytometry was performed with a Cytomation MO-Flo flow cytometer (Fort Collins, CO, USA) on single cell thymocyte suspensions using CD4 and CD8 antibodies from BD Pharmingen (San Diego, CA, USA) according to standard protocols.
Western blotting
Western blotting was performed according to standard procedures. Briefly, 15-40 mg of protein was separated on 10% polyacrylamide gels, transferred to Hybond C using semidry transfer, blocked with 4% fat-free milk powder, 1% FCS in PBS containing 0.01% Tween-20 and incubated overnight at 4 C with rabbit polyclonal antibodies against p53, Ets2, Bax (Santa Cruz), Bcl2 (Calbiochem) or b-tubulin (Boehringer). After three washings with PBS with 0.01% Tween-20 the membranes were incubated for 1-2 h at room temperature (RT) with appropriate HRP-conjugated secondary antibodies (DAKO, Denmark), followed by another 1 h wash. Supersignal (Calbiochem) chemiluminescent detection of HRP was subsequently used to visualize the cross reacting proteins. Betatubulin expression and protein concentration were used to normalize protein loading for each sample.
Immunohistochemistry
Cryosections of 10 mM from thymus and spleen were fixed in PBS containing 4% paraformaldehyde and 0.05% glutaraldehyde for 10 min at RT and washed in PBS. Endogenous peroxidases were inactivated with 3% H 2 O 2 for 20 min at RT. Sections were washed in PBS, blocked in CAS block (Zymed, CA, USA) for 30 min and incubated overnight at 4 C with a 1:50 dilution of a commercially available Ets2 antibody (Santa Cruz, C-351 X) in CAS blocking solution. Sections were washed three times in PBS with 0.01% tween-20 and incubated with a 1:100 dilution of anti-rabbit HRP (DAKO, Denmark). Brown immuno-reactivity was detected with DAB as a substrate.
Apoptosis assays
Apoptosis was determined as the amount of cells in the sub-G0 peak after propidium iodide staining of ethanol fixed cells. Briefly, the culture supernatant was collected and centrifuged at 2000 g for 5 min. Adherent cells were harvested by trypsiniation and mixed with the culture supernatant and centrifuged another 10 min at 2000 g. The pellet was washed once with PBS, resuspended in 90% EtOH and kept overnight at À20 C. Fixed cells were pelleted and stained for at least 1 h with 20 mg/ml propidium iodide in PBS containing 10 mg/ml RNase A. In situ detection of apoptosis via TUNEL was performed on 10 mM cryosections from thymus and spleen according to the manufacturer's instructions using the Apoptag kit from Intergen (Oxford, UK). DNA laddering was determined as described in Solovyan and Salminen (47) .
